Ginkgo Bioworks announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARPA-H...
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...
Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...
VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad populati...
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...
New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuse...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-m...
Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived p...
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Enables manufacturing...
© 2026 Biopharma Boardroom. All Rights Reserved.
